The objective of this Multidisciplinary Clinical Research Center at the Medical University of South Carolina is the advancement of knowledge with respect to African Americans who have, or who are at risk of developing, systemic lupus erythematosus, systemic sclerosis, and other debilitating rheumatic diseases. The Center is built on a solid framework of strong leadership in Rheumatology, Biostatistics and Health Disparities Research coupled with trust and a proven track record of recruitment of African American patients for clinical research. Objectives of the Center are to: 1) conduct and foster translational clinical research leading to improved diagnosis, management and ultimately a reduction or elimination of health disparities with respect to debilitating rheumatic diseases in African Americans;2) focus on identifying and understanding the underlying reasons for differences in risk profiles and disease progression for African Americans;3) provide information and education to patients and families, healthcare providers, the general public, investigators and health professionals at other academic health centers and government agencies. We propose two innovative, high impact projects supported by three cores. Project 1 will investigate a genetic variant observed in African American SSc patients likely to be responsible for their higher severity of pulmonary fibrosis. This is highly significant given the morbidity and mortality rates, especially related to lung disease, in these patients. Project 2 addresses another significant health disparity, the increasing prevalence of lupus among African American women. The Sea Island Gullah people of South Carolina and individuals living in the Gullah ancestral home of Sierra Leone provide a novel opportunity to study genetic, environmental and epigenetic differences that might identify key factors associated with the development of SLE in African Americans. These two projects and future pilot projects will be served by three cores: (1) a Methodology Core will provide rigorous methodological and biostatistical support;(2) a Patient Resource Core will assure investigators access to patients and biological samples from SSc and SLE patients enriched with African Americans;(3) an Administrative Core will coordinate the work of the Center through planning, development, coordination and overall administration. With a sustained commitment of strong institutional support and through a robust pilot project program, this MCRC will attract and nurture young investigators with research interests in minority health and rheumatic diseases.

Public Health Relevance

The ultimate goal of the Center is to facilitate the translation of research to the clinical arena and to support much needed genetic and environmental research on rheumatic diseases affecting minorities and women disproportionately. The proposed projects and cores are focused on two autoimmune connective tissue diseases, scleroderma and lupus, each of which has profound implications for the health of the public, and each of which has a disproportionate impact on the African American community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR062755-02
Application #
8493999
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Wang, Yan Z
Project Start
2012-07-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$1,095,546
Indirect Cost
$435,757
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Midgett, Kristin; Peden-Adams, Margie M; Gilkeson, Gary S et al. (2015) In vitro evaluation of the effects of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) on IL-2 production in human T-cells. J Appl Toxicol 35:459-65
Bogatkevich, Galina S; Nietert, Paul J; Silver, Richard M et al. (2014) Rationale for anticoagulant therapy of pulmonary fibrosis. Am J Respir Crit Care Med 189:362-3
Freedman, Barry I; Langefeld, Carl D; Andringa, Kelly K et al. (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:390-6
Akter, Tanjina; Silver, Richard M; Bogatkevich, Galina S (2014) Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep 16:411
Barnado, April; Wheless, Lee; Meyer, Anna K et al. (2014) Pregnancy outcomes among African-American patients with systemic lupus erythematosus compared with controls. Lupus Sci Med 1:e000020
Carroll, Rachel; Lawson, Andrew B; Voronca, Delia et al. (2014) Spatial environmental modeling of autoantibody outcomes among an African American population. Int J Environ Res Public Health 11:2764-79
Young, K A; Terrell, D R; Guthridge, J M et al. (2014) Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-9
Fan, Ming-Hui; Feghali-Bostwick, Carol A; Silver, Richard M (2014) Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol 26:630-6
Williams, Edith M; Kamen, Diane; Penfield, Megan et al. (2014) Stress Intervention and Disease in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies (BLESS) Study. Health (Irvine Calif) 6:71-79
Williams, Edith M; Penfield, Megan; Kamen, Diane et al. (2014) An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies Study. Open J Prev Med 4:22-31

Showing the most recent 10 out of 21 publications